The Pharma 5: What to know now in Pharma and Med Device litigation
United States | Video | May 2022 | 4:05
Video Details
[1] 00:00:00.000 [0] --> 00:00:03.733 [112]
I’m Madison Gaona and this is Norton
Rose Fulbright’s The Pharma 5.
[2] 00:00:13.633 [409] --> 00:00:17.567 [527]
Philips is breathing a little uneasily
this month as the company's CPAP
[3] 00:00:17.567 [527] --> 00:00:20.800 [624]
and BiPAP machine recall has spurred
a class action lawsuit.
[4] 00:00:21.400 [642] --> 00:00:23.267 [698]
The machines contain PE-PUR foam,
[5] 00:00:23.267 [698] --> 00:00:26.667 [800]
which allegedly can degrade under certain
conditions and cause cancer
[6] 00:00:26.667 [800] --> 00:00:28.000 [840]
and respiratory inflammation.
[7] 00:00:28.533 [856] --> 00:00:31.933 [958]
Baird Respiratory and other retailers
have filed the action in
[8] 00:00:31.933 [958] --> 00:00:34.900 [1047]
the Eastern District of Pennsylvania
alleging negligence,
[9] 00:00:34.900 [1047] --> 00:00:36.433 [1093]
fraud and breach of warranty,
[10] 00:00:36.767 [1103] --> 00:00:38.800 [1164]
claiming that Philips had
been aware of the foam
[11] 00:00:38.800 [1164] --> 00:00:41.533 [1246]
and unreasonably continued
to profit from its sales.
[12] 00:00:43.833 [1315] --> 00:00:48.433 [1453]
Discount or Miscount? Walgreens Prescriptions
Savings Club Program offers
[13] 00:00:48.433 [1453] --> 00:00:51.500 [1545]
a wide variety of prescription
drugs at discounted prices.
[14] 00:00:51.833 [1555] --> 00:00:55.600 [1668]
Several TPPs, however, have brought
suit in Illinois Federal Court,
[15] 00:00:55.800 [1674] --> 00:01:00.100 [1803]
alleging that Walgreens fraudulently
requested reimbursement benefits from TPPs
[16] 00:01:00.267 [1808] --> 00:01:01.833 [1855]
without the appropriate discount,
[17] 00:01:02.033 [1861] --> 00:01:04.933 [1948]
resulting in hundreds of millions
of dollars in overages.
[18] 00:01:05.233 [1957] --> 00:01:07.833 [2035]
The TPPs argued that the scheme undermines
[19] 00:01:07.833 [2035] --> 00:01:11.833 [2155]
the purpose of any health insurance company’s
prescription drug benefit program;
[20] 00:01:12.000 [2160] --> 00:01:15.167 [2255]
that is TPPs don’t pay
more than cash customers.
[21] 00:01:17.900 [2337] --> 00:01:20.267 [2408]
Now, a failure to warn trifecta.
[22] 00:01:23.300 [2499] --> 00:01:25.567 [2567]
In the securities arena, Judge Lewis J.
[23] 00:01:25.567 [2567] --> 00:01:28.400 [2652]
Liman of the Southern District
of New York has dismissed
[24] 00:01:28.400 [2652] --> 00:01:31.667 [2750]
an investor action filed against
Intercept Pharmaceuticals.
[25] 00:01:32.100 [2763] --> 00:01:35.600 [2868]
The investors allege that the company
failed to warn of fatalities
[26] 00:01:35.600 [2868] --> 00:01:40.400 [3012]
and other adverse events from use of Ocaliva,
a drug designed to treat liver disease,
[27] 00:01:40.600 [3018] --> 00:01:43.367 [3101]
while the co-founder sold his
stock at inflated price.
[28] 00:01:43.667 [3110] --> 00:01:46.867 [3206]
The shareholders, however, have failed
to adequately plead causation.
[29] 00:01:47.200 [3216] --> 00:01:49.133 [3274]
Only two adverse events had occurred,
[30] 00:01:49.133 [3274] --> 00:01:52.367 [3371]
both of which plaintiffs failed
to causally link to Ocaliva.
[31] 00:01:55.633 [3469] --> 00:01:59.133 [3574]
An atypical preemption response
on atypical fractures.
[32] 00:01:59.533 [3586] --> 00:02:04.100 [3723]
New Jersey federal Judge Freda Wolfson has
ruled that Albrecht preempts plaintiff’s
[33] 00:02:04.100 [3723] --> 00:02:08.667 [3860]
state law failure to warn claims involving
the osteoporosis drug Fosamax.
[34] 00:02:09.233 [3877] --> 00:02:14.367 [4031]
Merck had proposed to the FDA various
atypical fracture label changes in the ADR
[35] 00:02:14.367 [4031] --> 00:02:16.133 [4084]
and warning and precautions sections.
[36] 00:02:16.333 [4090] --> 00:02:20.600 [4218]
The FDA added the ADR language, but
rejected the proposed W&P additions.
[37] 00:02:20.733 [4222] --> 00:02:24.167 [4325]
There was not, quote, reasonable evidence
of a causal association, end quote,
[38] 00:02:24.200 [4326] --> 00:02:26.533 [4396]
as required by the regs. The
court ruled it was clear
[39] 00:02:26.533 [4396] --> 00:02:29.433 [4483]
the FDA would have rejected any
proposed warning at the time.
[40] 00:02:31.767 [4553] --> 00:02:34.600 [4638]
And finally, one hand, giveth.
The Ninth Circuit,
[41] 00:02:34.600 [4638] --> 00:02:39.133 [4774]
has shockingly interpreted California drug
and device failure to warn causation law
[42] 00:02:39.167 [4775] --> 00:02:42.400 [4872]
as deficient and requested instruction
on the issue from
[43] 00:02:42.400 [4872] --> 00:02:46.033 [4981]
the State Supreme Court. In Hymes
versus Somatics LLC,
[44] 00:02:46.233 [4987] --> 00:02:49.733 [5092]
the plaintiff allegedly suffered
permanent cognitive damage from
[45] 00:02:49.733 [5092] --> 00:02:53.000 [5190]
an ECT therapy machine manufactured
by Somatics.
[46] 00:02:53.667 [5210] --> 00:02:57.767 [5333]
The federal trial court granted a defense
summary judgment on causation grounds.
[47] 00:02:58.033 [5341] --> 00:03:01.033 [5431]
There was no evidence that a stronger
warning would have changed
[48] 00:03:01.033 [5431] --> 00:03:03.400 [5502]
the doctor’s decision to prescribe the ECT.
[49] 00:03:03.933 [5518] --> 00:03:08.233 [5647]
The Ninth Circuit, however, has found that
while it is clear under California failure
[50] 00:03:08.233 [5647] --> 00:03:11.667 [5750]
to warn causation law that a plaintiff
must show, one, that
[51] 00:03:11.667 [5750] --> 00:03:14.133 [5824]
the warning provided was inadequate, and two,
[52] 00:03:14.133 [5824] --> 00:03:17.100 [5913]
that the inadequacy of the warning
caused the plaintiff’s injury,
[53] 00:03:17.400 [5922] --> 00:03:20.333 [6010]
California law has not resolved
the question of how
[54] 00:03:20.567 [6017] --> 00:03:24.333 [6130]
the stronger warning must have altered the
content of the prescribing physician.
[55] 00:03:24.533 [6136] --> 00:03:29.433 [6283]
So in a move that could upend pharma and
medical device litigation in California,
[56] 00:03:29.767 [6293] --> 00:03:33.267 [6398]
the Ninth Circuit has certified for
the California Supreme Court
[57] 00:03:33.267 [6398] --> 00:03:36.667 [6500]
the following question: Is the plaintiff
required to show that
[58] 00:03:36.667 [6500] --> 00:03:39.167 [6575]
a stronger risk warning than
given would have altered
[59] 00:03:39.167 [6575] --> 00:03:43.233 [6697]
the physician’s decision to prescribe?
Obviously we’re pulling for a yes,
[60] 00:03:43.367 [6701] --> 00:03:45.433 [6763]
which we all thought was already the law.
[61] 00:03:48.667 [6860] --> 00:03:53.067 [6992]
Thanks for watching. See you next time on
Norton Rose Fulbright’s The Pharma 5.
This month, Madison Gaona, an associate in Dallas whose practice focuses on complex commercial and tort litigation, discusses:
- PE-PUR foam
- Drug discounts
- Failure to warn – securities
- Fosamax
- California failure to warn – causation